Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany

Epilepsy and Behavior

Volumn 27, Issue 3, 2013, Pages 433-438

  Strzelczyk, Adam ^a   Haag, Anja ^a   Reese, Jens P ^a   Nickolay, Tanja ^a   Oertel, Wolfgang H ^a   Dodel, Richard ^a   Knake, Susanne ^a   Rosenow, Felix ^a   Hamer, Hajo M ^b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Cost; Economic burden; Epilepsy; Indirect cost; Resource use; Retirement; Seizure; Work loss

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENYTOIN; PREGABALIN; PRIMIDONE; RUFINAMIDE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ADULT; ARTICLE; CROSS-SECTIONAL STUDY; DISEASE COURSE; EPILEPSY; FEMALE; FOCAL EPILEPSY; GERMANY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; RETIREMENT; SOCIAL STATUS; THERAPY; UNEMPLOYMENT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; COHORT STUDIES; COSTS AND COST ANALYSIS; CROSS-SECTIONAL STUDIES; EPILEPSY; FEMALE; GERMANY; HEALTH RESOURCES; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; PRESCRIPTION DRUGS; QUESTIONNAIRES; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84876438165     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2013.03.007     Document Type: Article

References (61)

1. Kwan P., Brodie M.J. Early identification of refractory epilepsy. N Engl J Med 2000, 342:314-319.
2. Beghi E., Garattini L., Ricci E., Cornago D., Parazzini F. Direct cost of medical management of epilepsy among adults in Italy: a prospective cost-of-illness study (EPICOS). Epilepsia 2004, 45:171-178.
3. Hamer H.M., Spottke A., Aletsee C., et al. Direct and indirect costs of refractory epilepsy in a tertiary epilepsy center in Germany. Epilepsia 2006, 47:2165-2172.
4. Jacoby A., Buck D., Baker G., McNamee P., Graham-Jones S., Chadwick D. Uptake and costs of care for epilepsy: findings from a U.K. regional study. Epilepsia 1998, 39:776-786.
5. Tetto A., Manzoni P., Millul A., et al. The costs of epilepsy in Italy: a prospective cost-of-illness study in referral patients with disease of different severity. Epilepsy Res 2002, 48:207-216.
6. Gustavsson A., Svensson M., Jacobi F., et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011, 21:718-779.
7. Strzelczyk A., Reese J.P., Dodel R., Hamer H.M. Cost of epilepsy: a systematic review. Pharmacoeconomics 2008, 26:463-476.
8. Helmers S.L., Duh M.S., Guerin A., et al. Clinical and economic impact of vagus nerve stimulation therapy in patients with drug-resistant epilepsy. Epilepsy Behav 2011, 22:370-375.
9. Helmers S.L., Paradis P.E., Manjunath R., et al. Economic burden associated with the use of generic antiepileptic drugs in the United States. Epilepsy Behav 2011, 18:437-444.
10. Forsgren I., Beghi E., Ekman M. Cost of epilepsy in Europe. Eur J Neurol 2005, 12(Suppl. 1):54-58.
11. Smeets V.M., van Lierop B.A., Vanhoutvin J.P., Aldenkamp A.P., Nijhuis F.J. Epilepsy and employment: literature review. Epilepsy Behav 2007, 10:354-362.
12. Haag A., Strzelczyk A., Bauer S., Kuhne S., Hamer H.M., Rosenow F. Quality of life and employment status are correlated with antiepileptic monotherapy versus polytherapy and not with use of "newer" versus "classic" drugs: results of the "Compliant 2006" survey in 907 patients. Epilepsy Behav 2010, 19:618-622.
13. Jacoby A. Stigma, epilepsy, and quality of life. Epilepsy Behav 2002, 3:10-20.
14. Begley C.E., Shegog R., Iyagba B., et al. Socioeconomic status and self-management in epilepsy: comparison of diverse clinical populations in Houston, Texas. Epilepsy Behav 2010, 19:232-238.
15. Jehi L., Tesar G., Obuchowski N., Novak E., Najm I. Quality of life in 1931 adult patients with epilepsy: seizures do not tell the whole story. Epilepsy Behav 2011, 22:723-727.
16. Brunetti M., Pagano E., Garattini L. The economic cost of epilepsy: a review. Ital J Neurol Sci 1998, 19:116-119.
17. van Hout B., Gagnon D., Souetre E., et al. Relationship between seizure frequency and costs and quality of life of outpatients with partial epilepsy in France, Germany, and the United Kingdom. Epilepsia 1997, 38:1221-1226.
18. Dodel R.C., Pepperl S., Kohne-Volland R., et al. Costs of drug treatment of neurologic diseases: Parkinson disease, dystonia, epilepsy. Med Klin (Munich) 1996, 91:479-485.
19. Knake S., Rosenow F., Vescovi M., et al. Incidence of status epilepticus in adults in Germany: a prospective, population-based study. Epilepsia 2001, 42:714-718.
20. Strzelczyk A., Nickolay T., Reese J.P., et al. Direct and indirect costs of refractory epilepsy in an epilepsy center in Germany. Neurol Rehabil 2008, 14:133-140.
21. Strzelczyk A., Nickolay T., Bauer S., et al. Evaluation of health-care utilization among adult patients with epilepsy in Germany. Epilepsy Behav 2012, 23:451-457.
22. Fisher R.S., van Emde Boas W., Blume W., et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005, 46:470-472.
23. Institute for Quality and Efficiency in Health Care (IQWiG) - technical document on cost estimation 09.10.2008 2008.
24. Schöffski O, v.d. Schulenburg J. Gesundheitsökonomische Evaluationen. 3., vollständig überarb. Aufl. ed. Berlin: Springer; 2007.
25. v.d.Schulenburg J.M., Greiner W., Jost F., et al. German recommendations on health economic evaluation: third and updated version of the Hanover Consensus. Value Health 2008, 11:539-544.
26. Arbeitsgemeinschaft Pharmazeutische Industrie, Bundesverband der Pharmazeutischen Industrie Rote Liste 2008, Editio Cantor [etc.], Aulendorf, [p. v.].
27. Krauth C., Hessel F., Hansmeier T., Wasem J., Seitz R., Schweikert B. Empirical standard costs for health economic evaluation in Germany - a proposal by the working group methods in health economic evaluation. Gesundheitswesen 2005, 67:736-746.
28. Spottke A.E., Reuter M., Machat O., et al. Cost of illness and its predictors for Parkinson's disease in Germany. Pharmacoeconomics 2005, 23:817-836.
29. Barber J.A., Thompson S.G. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med 2000, 19:3219-3236.
30. Dodel I., Reese J.P., Muller N., et al. Cost of illness in patients with Gilles de la Tourette's syndrome. J Neurol 2010, 257:1055-1061.
31. Winter Y., Wolfram C., Schaeg M., et al. Evaluation of costs and outcome in cardioembolic stroke or TIA. J Neurol 2009, 256:954-963.
32. Hong Z., Qu B., Wu X.T., Yang T.H., Zhang Q., Zhou D. Economic burden of epilepsy in a developing country: a retrospective cost analysis in China. Epilepsia 2009, 50:2192-2198.
33. Mesa T., Mesa J.T., Guarda J., et al. The direct costs of epilepsy in a Chilean population. Rev Neurol 2007, 44:710-714.
34. Garcia-Contreras F., Constantino-Casas P., Castro-Rios A., et al. Direct medical costs for partial refractory epilepsy in Mexico. Arch Med Res 2006, 37:376-383.
35. Sancho J., Pena P., Rufo M., Palacios G., Masramon X., Rejas J. Health and non-health care resources use in the management of adult outpatients with drug-resistant epilepsy in Spain: a cost-of-illness study (LINCE study). Epilepsy Res 2008, 81:176-187.
36. Jennum P., Gyllenborg J., Kjellberg J. The social and economic consequences of epilepsy: a controlled national study. Epilepsia 2011, 52:949-956.
37. Ivanova J.I., Birnbaum H.G., Kidolezi Y., Qiu Y., Mallett D., Caleo S. Economic burden of epilepsy among the privately insured in the US. Pharmacoeconomics 2010, 28:675-685.
38. Ivanova J.I., Birnbaum H.G., Kidolezi Y., Qiu Y., Mallett D., Caleo S. Direct and indirect costs associated with epileptic partial onset seizures among the privately insured in the United States. Epilepsia 2010, 51:838-844.
39. Geissler A., Scheller-Kreinsen D., Quentin W., Busse R. DRG systems in Europe. Incentives, purposes and differences in 12 countries. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2012, 55:633-642.
40. Federal Statistical Office (www.destatis.de) Labour market: registered unemployed, unemployment rate by area 1994-2011 2012.
41. Hamer H.M., Dodel R., Strzelczyk A., et al. Prevalence, utilization, and costs of antiepileptic drugs for epilepsy in Germany-a nationwide population-based study in children and adults. J Neurol 2012, 259:2376-2384.
42. Johannessen Landmark C., Fossmark H., Larsson P.G., Rytter E., Johannessen S.I. Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population. Epilepsy Res 2011, 95:51-59.
43. Tsiropoulos I., Gichangi A., Andersen M., Bjerrum L., Gaist D., Hallas J. Trends in utilization of antiepileptic drugs in Denmark. Acta Neurol Scand 2006, 113:405-411.
44. Marson A.G., Al-Kharusi A.M., Alwaidh M., et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 2007, 369:1000-1015.
45. Marson A.G., Al-Kharusi A.M., Alwaidh M., et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007, 369:1016-1026.
46. Rosenow F., Schade-Brittinger C., Burchardi N., et al. The LaLiMo trial: lamotrigine compared with levetiracetam in the initial 26weeks of monotherapy for focal and generalised epilepsy-an open-label, prospective, randomised controlled multicenter study. J Neurol Neurosurg Psychiatry 2012, 83:1093-1098.
47. Trinka E., Marson A.G., Van Paesschen W., et al. KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy. J Neurol Neurosurg Psychiatry 2013, 10.1136/jnnp-2011-300376.
48. Brodie M.J., Perucca E., Ryvlin P., Ben-Menachem E., Meencke H.J. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007, 68:402-408.
49. Begley C.E., Annegers J.F., Lairson D.R., Reynolds T.F., Hauser W.A. Cost of epilepsy in the United States: a model based on incidence and prognosis. Epilepsia 1994, 35:1230-1243.
50. Begley C.E., Famulari M., Annegers J.F., et al. The cost of epilepsy in the United States: an estimate from population-based clinical and survey data. Epilepsia 2000, 41:342-351.
51. Cockerell O.C., Hart Y.M., Sander J.W., Shorvon S.D. The cost of epilepsy in the United Kingdom: an estimation based on the results of two population-based studies. Epilepsy Res 1994, 18:249-260.
52. Krishnan A., Sahariah S.U., Kapoor S.K. Cost of epilepsy in patients attending a secondary-level hospital in India. Epilepsia 2004, 45:289-291.
53. Mak W., Fong J.K., Cheung R.T., Ho S.L. Cost of epilepsy in Hong Kong: experience from a regional hospital. Seizure 1999, 8:456-464.
54. Murray M.I., Halpern M.T., Leppik I.E. Cost of refractory epilepsy in adults in the USA. Epilepsy Res 1996, 23:139-148.
55. Nsengiyumva G., Druet-Cabanac M., Nzisabira L., Preux P.M., Vergnenegre A. Economic evaluation of epilepsy in Kiremba (Burundi): a case-control study. Epilepsia 2004, 45:673-677.
56. Thomas S.V., Sarma P.S., Alexander M., et al. Economic burden of epilepsy in India. Epilepsia 2001, 42:1052-1060.
57. Pfäfflin M., May T., Stefan H., Adelmeier U. Impact of epilepsy on daily living and employment of patients in primary care. Neurol Rehabil 2000, 6:140-148.
58. Thorbecke R., Specht U. Rehabilitation und Berufstätigkeit bei Menschen mit Epilepsie. TW Neurol Psychiatr 1993, 7:283-288.
59. Marinas A., Elices E., Gil-Nagel A., et al. Socio-occupational and employment profile of patients with epilepsy. Epilepsy Behav 2011, 21:223-227.
60. Begley C.E., Annegers J.F., Lairson D.R., Reynolds T.F. Methodological issues in estimating the cost of epilepsy. Epilepsy Res 1999, 33:39-55.
61. Koopmanschap M.A., Rutten F.F., van Ineveld B.M., van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ 1995, 14:171-189.